You are not logged in.

Treat cancers by targeting survivin: just a dream or future reality?

Coumar, Mohane Selvaraj, Tsai, Fang-Ying, Kanwar, Jagat Rakesh, Sarvagalla, Sailu and Cheung, Chun Hei Antonio 2013, Treat cancers by targeting survivin: just a dream or future reality?, Cancer treatment reviews, vol. 39, no. 7, pp. 802-811, doi: 10.1016/j.ctrv.2013.02.002.

Attached Files
Name Description MIMEType Size Downloads

Title Treat cancers by targeting survivin: just a dream or future reality?
Author(s) Coumar, Mohane Selvaraj
Tsai, Fang-Ying
Kanwar, Jagat Rakesh
Sarvagalla, Sailu
Cheung, Chun Hei Antonio
Journal name Cancer treatment reviews
Volume number 39
Issue number 7
Start page 802
End page 811
Total pages 10
Publisher Elsevier
Place of publication Amsterdam, The Netherlands
Publication date 2013-11
ISSN 1532-1967
Keyword(s) BIRC5
LY2181308
SPC3042
Survivin
YM155
Animals
Antineoplastic Agents
Apoptosis
DNA Repair
Drug Resistance, Neoplasm
Humans
Immunotherapy
Inhibitor of Apoptosis Proteins
Mitosis
Molecular Targeted Therapy
Neoplasms
Oligonucleotides, Antisense
Peptidomimetics
Science & Technology
Life Sciences & Biomedicine
Oncology
Summary Since the discovery of survivin (BIRC5) as a cancer-related molecule by Grazia Ambrosini and Dario C. Altieri at 1997, our knowledge related to the function of this molecule has been extended from simple apoptosis inhibition to complicated, interlinked processes that involve interference of mitosis, apoptosis, autophagy, and even DNA repair recently. However, despite the growing amount of knowledge related to survivin in the last ten years, the development of survivin inhibitors or survivin-related molecular therapies is surprisingly and relatively slow as compared to other therapeutic inhibitors for cancer treatment. Here, the molecular functions of survivin and the progress of development of survivin-targeting therapies are discussed in detail. Functional differences between different survivin-specific inhibitors are discussed from both structural and biochemical point of views. This review also reveals different challenges that scientists are currently facing in the development of survivin inhibitors for clinical application. Finally, future directions for the development of survivin-targeted therapies are discussed in this review.
Language eng
DOI 10.1016/j.ctrv.2013.02.002
Field of Research 111299 Oncology and Carcinogenesis not elsewhere classified
1112 Oncology And Carcinogenesis
Socio Economic Objective 920102 Cancer and Related Disorders
HERDC Research category C1.1 Refereed article in a scholarly journal
Copyright notice ©2013, Elsevier Ltd
Persistent URL http://hdl.handle.net/10536/DRO/DU:30067548

Document type: Journal Article
Collection: School of Medicine
Connect to link resolver
 
Unless expressly stated otherwise, the copyright for items in DRO is owned by the author, with all rights reserved.

Versions
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 63 times in TR Web of Science
Scopus Citation Count Cited 66 times in Scopus
Google Scholar Search Google Scholar
Access Statistics: 18 Abstract Views, 2 File Downloads  -  Detailed Statistics
Created: Mon, 02 Feb 2015, 10:44:00 EST

Every reasonable effort has been made to ensure that permission has been obtained for items included in DRO. If you believe that your rights have been infringed by this repository, please contact drosupport@deakin.edu.au.